CTOs on the Move

POINTONE Systems

www.pointone.ws

 
POINTONE Systems is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pointone.ws
  • 10437 W Innovation Dr
    Milwaukee, WI USA 53226
  • Phone: 414.771.1802

Executives

Name Title Contact Details

Similar Companies

Pattern Bioscience

Pattern is building a dream team of scientists and visionaries dedicated to addressing this global problem with faster, smarter diagnostics for more precise treatment.

Coastal Pharma Group

Coastal Pharma Group is a Oxnard, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WISErg

Headquartered in Redmond, Washington, WISErg is a privately held bio-clean technology company that converts food scraps from sources like grocery stores and restaurants into valuable, organic fertilizer. The company utilizes a patent-pending, oxidative conversion technology to intercept nutrients from food scraps before they become waste.

Enthrive

Enthrive is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the body`s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmune`s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs and its next TCR therapeutic candidate, directed at MAGE A-10, is scheduled to enter the clinic in 2015. The Company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing eight of these through unpartnered research programs. Adaptimmune has over 150 employees and is located in Oxfordshire, UK and Philadelphia, USA.